What are the 1-year returns of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
The 1-year trailing return for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth is shown in the Trailing Returns section. It is compared against the Equity: Sectoral-Pharma category average and benchmark for context.
What are the 3-year returns of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
The 3-year CAGR for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth is in the Trailing Returns section, with benchmark and category comparisons.
What are the 5-year returns of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
The 5-year CAGR for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth is in the Trailing Returns section. 5-year CAGR is a standard metric for medium-term performance consistency.
What are the returns of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth since inception?
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth has delivered a CAGR of 21.39% since its launch. The fund's maximum historical drawdown has been -0.21%, indicating its worst peak-to-trough decline during this period. Since-inception returns capture performance across multiple market cycles and are most useful for evaluating long-term wealth creation.
How has ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth performed vs its category over the long term?
Performance vs category average across 1Y, 3Y, 5Y and 10Y periods is in the Trailing Returns section. Rolling returns show how consistently the fund beats its category over time.
What is the Sharpe ratio of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
The Sharpe ratio of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth is 1.17. Sharpe ratio measures risk-adjusted return — how much excess return the fund generates per unit of risk. A Sharpe above 1.0 is generally considered good; above 2.0 is excellent. The fund's alpha of 2.11% indicates the excess return generated over the benchmark for the same risk.
What is the alpha of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
The alpha of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth is 2.11% and beta is 0.96. A positive alpha means the fund has generated more return than the benchmark for the same level of systematic risk. An alpha of 2.11% indicates the fund manager (or index replication) has added value beyond what market exposure alone would have delivered.
What is the beta of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
The beta of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth is 0.96 (Sharpe: 1.17). Beta measures how sensitive the fund's returns are to market moves. A beta below 1.0 (0.96) means ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth tends to be less volatile than the benchmark — it falls less in downturns but may also gain less in sharp rallies.
What are the rolling returns of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
Rolling returns for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth across all 1Y, 3Y, 5Y investment windows are shown in the Rolling Returns section. Unlike trailing returns, rolling returns reveal how the fund has performed across all possible entry and exit dates — offering a much more complete picture of consistency.
How consistent are the period-wise returns of ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth?
Period-wise annual returns for ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct-Growth across each financial year are in the Period Returns section. This shows whether the fund has been positive in most years and how it has fared in bear markets.
